Cipla Ltd. Focuses its China Investment, Emphasizes Biosimilars
Published: Aug 14, 2012
August 13, 2012 -- Cipla, the Indian generic drug maker, pulled $72 million out of its 49% investment in China’s Desano Holdings, and then put between $20 million and $25 million into each of three Desano subsidiaries in which Cipla is already invested. The companies focus on biosimilars, API and finished drugs. The goal of the narrowed focus is to become more vertically integrated. More details....
Stock Symbol: (BSE: 500087)